article Open AccessTop 1% cited

Randomised clinical trial: the beneficial effects of <scp>VSL</scp>#3 in obese children with non‐alcoholic steatohepatitis

Alimentary Pharmacology & Therapeutics · 2014 · Vol. 39(11) · pp. 1276–1285

Anna Alisi(Istituti di Ricovero e Cura a Carattere Scientifico)Giorgio Bedogni(AREA Science Park)Giuseppe BavieraValentina Giorgio(Bambino Gesù Children's Hospital)E. PorroC. ParisPaola GiammariaLaura RealiFrank A. Anania(Emory University)Valério Nobili✉(Istituti di Ricovero e Cura a Carattere Scientifico)

View via DOI Full-text PDF

Abstract

A 4-month supplement of VSL#3 significantly improves NAFLD in children. The VSL#3-dependent GLP-1 increase could be responsible for these beneficial effects. Trial identifier: NCT01650025 (www.clinicaltrial.gov).

Liver Disease Diagnosis and Treatment Diet and metabolism studies Gut microbiota and healthMedicinePlaceboInternal medicineFatty liverGastroenterologySteatohepatitisInsulin resistanceAlanine transaminaseBody mass indexConfidence interval

MeSH terms

Alanine TransaminaseBiopsyChildDouble-Blind MethodFatty LiverFemaleHumansInsulin ResistanceMaleObesitySeverity of Illness IndexUltrasonographyBody Mass IndexTreatment OutcomeDietary Supplements

Citations

451

FWCI

24.45

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Gut Microbiota and Obesity: A Role for Probiotics